Thank you for subscribing!

Clear Insights, Improved Outcomes

Oncocyte: improving patient outcomes through better diagnosis and monitoring



When it comes to cancer treatment, information is key. 

The earlier doctors detect the cancer or progression, the earlier they can begin treatment. The more they know about the patient’s specific condition and status, the more targeted and effective their treatment can be.

While there are many companies in this space, none of them give physicians the same level of insight and information that Oncocyte Corporation (Nasdaq: OCX) does with their innovative suite of diagnostic and monitoring technologies.

Oncocyte’s mission is to improve patient outcomes, and they have the technology and the experience to give treating physicians more information, more accurately, faster than ever before.





Information that saves lives

Cancer treatment can be a matter of life and death. Oncocyte gives physicians the information they need to deliver the right treatment to the right patient.

Improved patient outcomes

Oncocyte’s mission is to improve patient outcomes, and the clearer insights and earlier detection their technology provides allows for increased confidence when making important treatment decisions.

Proven results

Oncocyte’s DetermaRx™ technology has already identified over 500 high risk recurring lung cancer patients, allowing earlier treatment intervention and increasing expected odds of survival by over 90%.

$5 billion market opportunity

Industry sources estimate this is the size of the cancer diagnosis and treatment market, and Oncocyte is already gaining significant traction with more to come.

Solid foundation for continued growth

With DetermaRx™ already delivering results and revenue, Oncocyte has a full development pipeline of additional tests, services for companies developing new drugs and treatments, and a recent acquisition providing exposure to the lucrative organ transplant testing market.



Oncocyte powers improved outcomes

A cancer diagnosis is a terrible piece of news for a patient to receive, but thanks to Oncocyte (Nasdaq: OCX), physicians are better able to diagnose, monitor, and treat cancer in a more precise, personalized way.

Better information in these cases can improve patient outcomes, and Oncocyte’s technology is already showing promising results.



DetermaRX™ saves lives

Launched in 2020, DetermaRx™ is a test that identifies patients with lung cancer who have a high risk of recurrence.

Untreated, nearly 50% of these patients would likely lose their lives within 5 years. Once identified as high risk, these patients are able to receive more appropriate treatment – in some cases chemotherapy – which can increase their survival rate to over 90%.

DetermaRx™ has already identified over 500 high risk patients for recurrence of lung cancer, allowing for prompt treatment and dramatically improved outcomes.



More tests in the pipeline

While DetermaRx™ is already delivering results, saving lives, and bringing in revenue, there is much more in the pipeline from Oncocyte.

Available for research only at the moment, DetermaIO™ is a gene expression test to assess the tumor microenvironment to predict response to immunotherapies. DetermaTx, currently in development, will assess mutational status of a tumor.

Also in development are DetermaCNI™, a blood based monitoring test, and DetermaMX™, a long-term recurrence monitoring test. 

Cancer diagnosis and treatment is a very technical field, and the bottom line is that Oncocyte’s tests will give attending physicians more information at critical decision points on the condition of the patients and the progression or remission of their cancer.





Educating doctors

When treating patients, information is power. So it follows that a technology like DetermaRx™ that provides more information and clearer insights would be an obvious decision for doctors to use in their practice.

Oncocyte’s experience has shown this to be true, so one of the biggest opportunities for the company right now is educating more doctors about the benefits of this product, and onboarding them to use it in their practice.

This is an area that Oncocyte has already seen considerable progress in, increasing the pool of prescribing physicians by 22% between Q2 and Q3 2021, 150% year over year, to a total of 367.

In the same time period, onboarded hospitals and sites increased 24% to a total of 218 sites. This was a 225% increase year over year.

Oncocyte has seen repeat prescriptions from onboarded doctors and sites, indicating that they are finding the tests valuable in the treatment of their patients. As more products become available, Oncocyte will continue their education efforts and hopefully see significant further growth.



Growing revenues

Even though several of their tests are still in development, DetermaRx™ continues to generate revenue growth for Oncocyte. In Q3 2021 alone, revenues were approximately $1 million, a 77% increase year over year. 

For the period of Q1 to Q3 2021, revenue was $4.1 million, a massive 480% increase year over year.

With more products coming online, more physicians and hospitals being onboarded, and repeat orders coming in, we are optimistic about the future for Oncocyte.




New Expansion Opportunities

Oncocyte Corporation recently announced a development and co-marketing agreement for two distributed in vitro diagnostic (IVD) assays on Thermo Fisher Scientific’s Ion Torrent™ Genexus™ System. Oncocyte has also been granted rights to develop future companion diagnostics on the Genexus System. This represents a huge opportunity to expand access to precision oncology. 

“As many as 44% of newly diagnosed cancer patients may be eligible for immuno-oncology therapies, with additional patients potentially benefiting from other precision medicines, yet many patients’ tumors are never sequenced to determine if they may benefit from these targeted treatments,” said Ron Andrews, President and Chief Executive Officer of Oncocyte. “In order to increase the number of patients benefiting from precision medicine, we need to expand the number of IVDs and develop these tests on instruments that are designed to make sequencing-based testing simple and more accessible.”

Mr. Andrews continued, “Leveraging Thermo Fisher’s proven global capabilities and installed base will enable us to expand the availability of IVD assays beyond the U.S. market, (and the collaboration) will play a key role in helping us improve patient outcomes worldwide.”

Supported by the first-of-its-kind Genexus System –  which is easier to use, and delivers same-day results in the right conditions – Oncocyte’s collaboration lays the groundwork for rapid expansion into new markets while delivering better diagnostics to patients around the world.




Pharmaceutical services for drug developers

The diagnosis and monitoring of cancer is critical for improving patient outcomes, but treatment, of course, is a key piece of the puzzle.

Oncocyte pharmaceutical services division provides a full suite of molecular testing services to companies developing new cancer treatments and drugs. This line of business represents another significant potential stream of revenue, and further supports Oncocyte’s mission of improving patient outcomes.



Summary For Investors

Oncocyte is a precision diagnostics company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer.

With clinical success and increasing revenues, the Company’s DetermaRx™ diagnostic test is already gaining significant support and traction among physicians and hospitals. 

Oncocyte has multiple promising cancer diagnostic and research tests in the pipeline, and through a recent acquisition, has exposure to the lucrative $2 billion organ transplant testing market.

With an experienced team and proven science already producing cutting edge diagnostic technology, the future for Oncocyte is looking bright. 

Oncocyte’s mission is to improve patient outcomes, and they are already well on their way to doing exactly that. For investors, a position in Oncocyte could be a very profitable way to gain exposure to the booming medical testing market through a proven innovator in the space.



Press Releases



Ronald Andrews

President and CEO

Ronnie has over 35 years of experience in the Global Clinical and Molecular Diagnostics industry. He currently serves as the President and CEO of Oncocyte Inc. In his early years in diagnostics, he worked for Abbott Diagnostics in sales and marketing, Immucor as VP of Marketing and Product Development, and the SVP Operations for Roche Molecular Diagnostics.

Mitch Levine

Chief Financial Officer

Mitch joined Oncocyte Corp as Chief Financial Officer in November of 2017 and is responsible for all aspects of financial management and corporate reporting, and is one the most experienced executives globally in capital markets.

Gisela Paulsen

Chief Operating Officer

Gisela was appointed Chief Operating Officer of Oncocyte Corporation in October 2021, and brings with her over two decades of experience as a cross-functional leader, with an extensive scientific and operational background leading large-scale global change management and driving commercial and drug development innovation at global pharmaceutical and diagnostics companies.

Doug Ross MD, PhD

Chief Science Officer

Prior to joining Oncocyte, Dr. Doug Ross was a founding principal in the Bethesda Group, LLC, a boutique consulting firm that provided technical, commercial and operational expertise to the diagnostic and pharma industry. He is an experienced medical diagnostics R&D executive with a background in research and development at the intersections between genomics, proteomics and diagnostics.

Padma Sundar

Chief Commercial Officer

Padma has extensive experience in commercializing and driving market leadership for molecular diagnostics at Roche Sequencing, Guardant Health, and Affymetrix.

Prof. Dr. Ekkehard Schütz, MD PhD, FAACC

Chief Technology Officer

Ekkehard (Ekke) joined Oncocyte in April 2021 through the acquisition of Chronix Biomedical. Ekke serves as the managing director of Chronix Biomedical GmbH, wholly owned by Oncocyte and CMO for Europe. As an adjunct professor, he teaches molecular genetics and diagnostics at the Georg-August-University.


Who are we and what do we do? We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (the “Information”) about publicly traded companies (the “Profiled Issuers”). How is the Information published? We publish the Information on our Website, in newsletters, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer or third party paying us. Our publication of the Information is known as a “Campaign”. Will everyone receive the Information at the same time? No. The Information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. How is a potential investor impacted if he/she receives the Information later than other investors? Typically, the trading volume and price of a Profiled Issuer’s securities increases after the Information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he/she may suffer increased trading losses if he/she purchases the securities of a Profiled Issuer. What will happen when the Campaign ends? Most, if not all, of the Profiled Issuers are penny stocks that are illiquid and whose securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profiled Issuer will likely increase significantly. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment. Why do we publish only favorable Information? We only publish favorable information because we are compensated to publish only favorable information. Why don’t we publish negative Information? We don’t publish negative information because we are not paid to publish negative information. We are paid to publish only favorable information. Is the Information complete, accurate, truthful or reliable? No. The Information is a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. What we do not do? We do not publish negative information about the Profiled Issuers. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities. Where does the Information come from? The Information is provided to us by the Profiled Issuers and/or the person who hires us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, the Securities and Exchange Commission’s Edgar database or other available public sources. If we say we make “stock picks,” are those picks our own? No, they are not. We are compensated to advertise the securities we are told to advertise. What will happen if an investor relies on the Information? If an investor relies on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision. Who pays us to publish the Information? The source of our compensation varies depending upon the particular circumstances of the Campaign. We are compensated by the Profiled Issuers, third party shareholders and other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities. The nature and amount of compensation we receive for publishing the Information about each Profiled Issuer and our ownership of each Profiled Issuer is set forth below under the heading captioned, “What we are compensated”. What warranties do we make about the Information? None. We make no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation. What we are not. We are not and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following:
  • An independent adviser or consultant;
  • A fortune teller;
  • An investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
  • A broker-dealer or an individual acting in the capacity of a registered representative or broker;
  • A stock picker;
  • A securities trading expert;
  • A securities researcher or analyst;
  • A financial planner or one who engages in financial planning;
  • A provider of stock recommendations;
  • A provider of advice about buy, sell or hold recommendations as to specific securities; or
  • An agent offering or securities for sale or soliciting their purchase.
Are risks in this disclaimer the only risks investors should be aware of? No. There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer. What conflicts of interest do we have in publishing the Information? We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. Our publication of the Information involves actual and material conflicts of interest including but not limited to the following:
  • We receive monetary and/or securities compensation in exchange for publishing the (favorable) Information about the Profiled Issuers;
  • We do not publish any negative information whatsoever about the Profiled Issuers;
  • We may own a Profiled Issuer’s securities that we acquired from the Profiled Issuer, third parties or from our own open market purchases before, during or after the Campaign and we may sell these securities during the Campaign while publishing the (favorable) information that instructs investors to purchase. Our selling of a Profiled Issuer’s securities will likely cause investors to suffer losses;
  • A short time after we acquire a Profiled Issuer’s payment via cash or securities, we may publish the (favorable) Information about the Profiled Issuer advising others, including you, to purchase; and while doing so, we may sell the Profiled Issuer’s securities we acquired during our public dissemination of the Information causing us to profit while you suffer a loss;
  • Parties holding a Profiled Issuer’s securities, including those who engage our services and/or compensate us, will sell their shares of the Profiled Issuer while we are publishing the (favorable) Information.
Who is responsible if an investor relies on the Information? The investor. We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions or errors in the Information, and we are not responsible for actions taken by any person who relies upon the Information. What do we urge potential investors to do? We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, OTC Markets, NASDAQ, NYSE, or other available public sources. Why is this Disclaimer being provided? We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose our compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell our own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns. What are other risks that investors should be aware of? Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.
  • We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.
  • If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
  • The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.
  • The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.
  • You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.
  • We or other stock promoters may receive free trading shares as compensation or we may acquire such shares in open market transactions before and during the Campaigns, and we may sell the shares we acquire at any time, even during the Campaigns while publishing the Favorable Information. When we sell the shares of the Profiled Issuers that we hold, the price at which investors can sell their shares will dramatically decrease and will likely cause investors to suffer trading losses.
  • We may sell securities of the Profiled Issuers for less than target prices set forth in the Information, and we may profit by selling our securities during the Campaigns while investors encounter losses.
  • When we acquire, purchase or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit us to make substantial profits while investors who purchase during the Campaign experience significant losses.
  • The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.
  • If we are compensated in improperly free trading securities of the Profiled Issuers, either directly or indirectly from persons who claim to be non-affiliates of such Profiled Issuer, we and the Profiled Issuer or third party could be subject to SEC Enforcement Action, including allegations of an illegal distribution in violation of Section 5(a) and 5(c) of the Securities Act.
  • We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and fail to disclose their compensation to you.
If a Profiled Issuer is an SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions. If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies. The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at, or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at and You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at What we were paid to advertise the Profiled Issuers. The details of our compensation and the period of the Campaign is set forth below.
  • Name of Issuer & Ticker Symbol - OncoCyte Corporation (OCX)
  • Amount & Form of Compensation - $35,000 in USD
  • Who Paid for the Campaign & Position with Company if any - OncoCyte Corporation (OCX)
  • Period of Campaign - 1/6/2022 - 2/6/2022

Related Post

Register to Download the Presentation

Go to website
Go to top